Hemizygous CDKN2A deletion confers worse survival outcomes in IDHmut-noncodel gliomas
Kocakavuk E, Johnson K, Sabedot T, Reinhardt H, Noushmehr H, Verhaak R. Hemizygous CDKN2A deletion confers worse survival outcomes in IDHmut-noncodel gliomas. Neuro-Oncology 2023, 25: 1721-1723. PMID: 37329568, PMCID: PMC10479907, DOI: 10.1093/neuonc/noad095.Peer-Reviewed Original ResearchAstrocytomaBrain NeoplasmsCyclin-Dependent Kinase Inhibitor p16GliomaHumansIsocitrate DehydrogenaseMutation